专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2011157372A Method of treating functional bowel disorder 审中-公开
标题翻译：治疗功能性贝叶斯病的方法
公开(公告)号：JP2011157372A
公开(公告)日：2011-08-18
申请号：JP2011061194
申请日：2011-03-18
申请人： Dynogen Pharmaceuticals Inc , ダイノゲンファーマシューティカルズ,インコーポレイテッド
发明人： LANDAU STEVEN B
IPC分类号： A61K31/519 , A01N43/00 , A01N43/54 , A61K20060101 , A61K31/505 , A61K31/55 , A61K31/551 , A61K45/06 , A61P1/00 , A61P1/04 , A61P1/12 , A61P43/00 , C07D495/04
CPC分类号： A61K31/505 , A61K31/519 , A61K31/55 , A61K31/551 , A61K45/06 , A61K2300/00
摘要： PROBLEM TO BE SOLVED: To provide a method of treating functional bowel disorders, more particular a therapeutic method for irritable bowel syndrome.
SOLUTION: The therapeutic method for irritable bowel syndrome using a compound expressed by formula I is provided (wherein R
1 and R
2 are each hydrogen, a halogen or the like; R
3 and R
4 are each hydrogen or alkyl; R
5 is hydrogen, alkyl or the like; Ar is phenyl, thienyl or the like; and n is 2 or 3).
COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译：要解决的问题：提供治疗功能性肠病的方法，更具体地，涉及肠易激综合征的治疗方法。提供了使用由式I表示的化合物的肠易激综合征的治疗方法（其中R 1 和R SB 2 各自为氢，卤素或 R 3 SB 3和R SB 4各自为氢或烷基; R 5为氢，烷基等; Ar为苯基，噻吩基或类似物; n为2或3）。版权所有（C）2011，JPO＆INPIT

2. 发明申请

US20040209869A1 Method of treating lower urinary tract disorders 失效
标题翻译：治疗下尿路疾病的方法
公开(公告)号：US20040209869A1
公开(公告)日：2004-10-21
申请号：US10817332
申请日：2004-04-02
申请人： Dynogen Pharmaceuticals, Inc.
发明人： Steven B. Landau , Cheryl L. Miller , Mathew O. Fraser
IPC分类号： A61K031/551 , A61K031/519
CPC分类号： A61K31/519 , A61K31/00 , A61K31/551 , A61K31/5513 , A61K45/06 , A61K2300/00
摘要： The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.
摘要翻译：本发明涉及一种治疗需要治疗的受试者的下尿路疾病的至少一种症状的方法，其中所述症状选自尿频，尿急，尿急迫性尿失禁，夜尿和遗尿。该方法包括向需要治疗的受试者施用治疗有效量的具有5-HT 3受体拮抗剂活性的化合物和NorAdrenaline再摄取抑制剂（NARI）活性。本发明还涉及在需要治疗的受试者中治疗下尿路障碍的至少一种症状的方法，其中所述症状选自尿频，尿急，尿急迫性尿失禁，夜尿和遗尿，包括向所述受试者共同施用第一量的5-HT 3拮抗剂和第二量的NARI，其中第一和第二量一起包含治疗有效量或者以治疗有效量存在。

3. 发明申请

US20040248979A1 Method of treating lower urinary tract disorders 审中-公开
标题翻译：治疗下尿路疾病的方法
公开(公告)号：US20040248979A1
公开(公告)日：2004-12-09
申请号：US10859922
申请日：2004-06-03
申请人： DYNOGEN PHARMACEUTICALS, INC.
发明人： Lee R. Brettman , Steven B. Landau , Matthew O. Fraser
IPC分类号： A61K031/195 , A61K031/137
CPC分类号： A61K31/137 , A61K31/195 , A61K2300/00
摘要： The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis comprising coadministering to said subject a first amount of an null2null subunit calcium channel ligand and a second amount of a substituted aminomethyl-phenyl-cyclohexane derivative, wherein the first and second amounts together comprise a therapeutically effective amount. The coadministration of a first amount of an null2null subunit calcium channel ligand and a second amount of a substituted aminomethyl-phenyl-cyclohexane derivative can result in an enhanced or synergistic therapeutic effect, wherein the combined effect is greater than the additive effect resulting from separate administration of the first amount of the null2null subunit calcium channel ligand and the second amount of the substituted aminomethyl-phenyl-cyclohexane derivative.
摘要翻译：本发明涉及治疗需要治疗的受试者中的下尿路障碍的至少一种症状的方法，其中所述症状选自尿频，尿急，尿急迫性尿失禁，夜尿和遗尿，包括共同施用所述受试者第一量的α2delta亚基钙通道配体和第二量的取代的氨基甲基 - 苯基 - 环己烷衍生物，其中第一和第二量一起包含治疗有效量。第一量的α2delta亚基钙通道配体和第二量的取代的氨基甲基 - 苯基 - 环己烷衍生物的共同给药可导致增强的或协同的治疗效果，其中组合效应大于由单独给药产生的加和效应的第一量的α2delta亚基钙通道配体和第二量的取代的氨基甲基 - 苯基 - 环己烷衍生物。

4. 发明申请

US20040147509A1 Method of treating functional bowel disorders 审中-公开
公开(公告)号：US20040147509A1
公开(公告)日：2004-07-29
申请号：US10757364
申请日：2004-01-13
申请人： Dynogen Pharmaceuticals, Inc.
发明人： Steven B. Landau
IPC分类号： A61K031/519
CPC分类号： A61K31/505 , A61K31/519 , A61K31/55 , A61K31/551 , A61K45/06 , A61K2300/00
摘要： The invention relates to a method of treating functional bowel disorders in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating a functional bowel disorder in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone. The functional bowel disorders which can be treated according to the method of the invention include IBS, functional abdominal bloating, functional constipation and functional diarrhea.

5. 发明申请

US20040213842A1 Methods of treating gastrointestinal tract disorders using sodium channel modulators 审中-公开
标题翻译：使用钠通道调节剂治疗胃肠道疾病的方法
公开(公告)号：US20040213842A1
公开(公告)日：2004-10-28
申请号：US10769071
申请日：2004-01-30
申请人： Dynogen Pharmaceuticals, Inc.
发明人： Edward C. Burgard , Steven B. Landau , Matthew Oliver Fraser
IPC分类号： A61K009/20
CPC分类号： A61K45/06 , A61K31/00 , A61K31/137 , A61K31/165 , A61K31/506 , A61K31/53 , A61K2300/00
摘要： The invention relates to methods of using sodium channel modulators, particularly TTX-R sodium channel modulators and/or activity dependent sodium channel modulators to treat gastrointestinal tract disorders, particularly inflammatory bowel disorders and irritable bowel syndrome.
摘要翻译：本发明涉及使用钠通道调节剂，特别是TTX-R钠通道调节剂和/或活性依赖性钠通道调节剂来治疗胃肠道疾病，特别是炎症性肠病和肠易激综合征的方法。

6. 发明申请

US20040192730A1 Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction 审中-公开
标题翻译：使用组合的5-HT1A和SSRI活性化合物治疗性功能障碍的方法
公开(公告)号：US20040192730A1
公开(公告)日：2004-09-30
申请号：US10799490
申请日：2004-03-12
申请人： Dynogen Pharmaceuticals, Inc.
发明人： Karl Bruce Thor
IPC分类号： A61K031/4545 , A61K031/506 , A61K031/501
CPC分类号： A61K31/437 , A61K31/40 , A61K31/404 , A61K31/4245 , A61K31/4365 , A61K31/4545 , A61K31/46 , A61K31/496 , A61K31/538
摘要： A method is provided for using compounds that exhibit combined activities as 5-HT1A active agents and selective serotonin reuptake inhibitors (SSRI's) to treat sexual dysfunction, particularly premature ejaculation, on an as-needed basis shortly before sexual activity.
摘要翻译：提供了一种使用化合物作为5-HT1A活性剂和选择性5-羟色胺再摄取抑制剂（SSRI's）的化合物在性活动前不久就根据需要治疗性功能障碍，特别是早泄的方法。

7. 发明申请

US20040147510A1 Method of treating nausea, vomiting, retching or any combination thereof 审中-公开
标题翻译：治疗恶心，呕吐，呕吐或其任何组合的方法
公开(公告)号：US20040147510A1
公开(公告)日：2004-07-29
申请号：US10757981
申请日：2004-01-13
申请人： Dynogen Pharmaceuticals, Inc.
发明人： Steven B. Landau , Cheryl L. Miller , Karl B. Thor
IPC分类号： A61K031/551 , A61K031/519
CPC分类号： A61K31/135 , A61K31/519 , A61K31/535 , A61K31/551 , A61K41/00 , A61K45/06 , A61K2300/00
摘要： The invention relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating nausea, vomiting, retching or any combination thereof in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone.
摘要翻译：本发明涉及在需要治疗的受试者中治疗恶心，呕吐，呕吐或其任何组合的方法。该方法包括向需要治疗的受试者施用治疗有效量的具有5-HT 3受体拮抗剂活性的化合物和NorAdrenaline再摄取抑制剂（NARI）活性。本发明还涉及在有需要的受试者中治疗恶心，呕吐，呕吐或其任何组合的方法，包括向所述受试者加入第一量的5-HT 3拮抗剂和第二量的NARI，其中第一并且第二量一起包含治疗有效量或者以治疗有效量存在。此外，本发明的方法包括单独施用NARI。

8. 发明申请

US20040209960A1 Methods of treating lower urinary tract disorders using sodium channell modulators 审中-公开
标题翻译：使用钠通道调节剂治疗下尿路疾病的方法
公开(公告)号：US20040209960A1
公开(公告)日：2004-10-21
申请号：US10769072
申请日：2004-01-30
申请人： Dynogen Pharmaceuticals, Inc.
发明人： Edward C. Burgard , Karl Bruce Thor , Matthew Oliver Fraser
IPC分类号： A61K031/137
CPC分类号： A61K45/06 , A61K31/13 , A61K31/135 , A61K31/137 , A61K31/138 , A61K31/165 , A61K31/195 , A61K31/35 , A61K31/357 , A61K31/365 , A61K31/37 , A61K31/38 , A61K31/53 , A61K31/55 , A61K2300/00
摘要： The invention relates to methods of using sodium channel modulators, particularly TTX-R sodium channel modulators and/or activity dependent sodium channel modulators to treat painful and non-painful lower urinary tract disorders, particularly painful and non-painful overactive bladder with and/or without loss of urine.
摘要翻译：本发明涉及使用钠通道调节剂，特别是TTX-R钠通道调节剂和/或活性依赖性钠通道调节剂来治疗疼痛和非痛苦的下尿路疾病，特别是疼痛和非疼痛的过度活动性膀胱和/或无尿。

9. 发明申请

US20040198775A1 Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using Cav2.2 subunit calcium channel modulators 失效
标题翻译：使用Cav2.2亚基钙通道调节剂治疗下尿路疾病和相关疾病外阴和外阴前庭炎的方法
公开(公告)号：US20040198775A1
公开(公告)日：2004-10-07
申请号：US10796952
申请日：2004-03-10
申请人： Dynogen Pharmaceuticals, Inc.
发明人： Matthew Oliver Fraser , Karl Bruce Thor , Edward C. Burgard
IPC分类号： A61K031/455
CPC分类号： A61K31/455 , A61K31/00
摘要： The invention relates to methods of using Cav2.2 subunit calcium channel modulators to treat painful and non-painfull lower urinary tract disorders and the related genitourinary tract disorders vulvodynia and vulvar vestibulitis in normal and spinal cord injured patients.
摘要翻译：本发明涉及使用Cav2.2亚基钙通道调节剂治疗正常和脊髓损伤患者的疼痛和非疼痛性下尿路疾病以及相关的泌尿生殖道疾病外阴和外阴前庭炎的方法。

10. 发明申请

US20040142034A1 Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators 审中-公开
标题翻译：使用α2delta亚基钙通道调节剂治疗非痛性膀胱病的方法
公开(公告)号：US20040142034A1
公开(公告)日：2004-07-22
申请号：US10741360
申请日：2003-12-19
申请人： Dynogen Pharmaceuticals, Inc.
发明人： Karl Bruce Thor , Edward C. Burgard , Matthew Oliver Fraser
IPC分类号： A61K009/22
CPC分类号： A61K31/195 , A61K31/197
摘要： A method is provided for treatment of non-painful bladder disorders, particularly non-painful overactive bladder without loss of urine. The method comprises administration of an null2null subunit calcium channel modulator, including gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, amino acid compounds, and other compounds that interact with the null2null calcium channel subunit.
摘要翻译：提供了一种用于治疗非痛性膀胱疾病，特别是非疼痛的膀胱过度活动症而不损失尿液的方法。该方法包括施用α2delta亚基钙通道调节剂，其包括加巴喷丁，加巴喷丁，GABA类似物，加巴喷丁的稠合双环或三环氨基酸类似物，氨基酸化合物和与α2dtata钙通道亚基相互作用的其它化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式